Centessa Pharmaceuticals plc

NASDAQ:CNTA

17.16 (USD) • At close December 20, 2024
Bedrijfsnaam Centessa Pharmaceuticals plc
Symbool CNTA
Munteenheid USD
Prijs 17.16
Beurswaarde 2,259,270,190
Dividendpercentage 0%
52-weken bereik 6.65 - 18.97
Industrie Biotechnology
Sector Healthcare
CEO Dr. Saurabh Saha M.D., Ph.D.
Website https://www.centessa.com

An error occurred while fetching data.

Over Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor,

Vergelijkbare Aandelen

Leafly Holdings, Inc. logo

Leafly Holdings, Inc.

LFLY

1.62 USD

MiMedx Group, Inc. logo

MiMedx Group, Inc.

MDXG

9.1 USD

Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc.

INO

1.84 USD

IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc.

IDYA

25.61 USD

Accolade, Inc. logo

Accolade, Inc.

ACCD

3.48 USD

Agenus Inc. logo

Agenus Inc.

AGEN

2.83 USD

Nuvalent, Inc. logo

Nuvalent, Inc.

NUVL

84.22 USD

RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc.

RAPT

0.825 USD

IRadimed Corporation logo

IRadimed Corporation

IRMD

54.65 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)